Related Experiment Video

Updated: Jul 19, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Integrating new targeted agents into the treatment of non-small-cell lung cancer

Nick Thatcher1

  • 1Christie and Wythenshawe Hospitals, Manchester, UK. nick.thatcher@christie-tr.nwest.nhs.uk

Lung Cancer (Amsterdam, Netherlands)
|October 24, 2006
PubMed

Insights

Targeted therapies for lung cancer show promise, but integrating epidermal growth factor receptor (EGFR) inhibitors into non-small cell lung cancer (NSCLC) treatment requires further study. Optimizing early treatment is key to improving long-term patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality globally, necessitating novel therapeutic strategies.
  • Targeted therapies, specifically those inhibiting the epidermal growth factor receptor (EGFR/HER1) pathway, represent a significant advancement in non-small cell lung cancer (NSCLC) treatment.

Purpose of the Study:

  • To explore the integration of novel EGFR/HER1 targeted agents into existing NSCLC treatment paradigms.
  • To clarify the impact of early-stage treatment decisions on overall patient outcomes in NSCLC.

Main Methods:

  • Review of current literature on EGFR/HER1 targeted therapies in NSCLC.
  • Analysis of clinical trial data regarding treatment sequencing and efficacy.
  • Discussion of challenges in optimizing targeted therapy implementation.

Main Results:

  • EGFR/HER1 targeted agents offer a new therapeutic class for NSCLC.
  • Optimal integration and sequencing of these agents remain areas for investigation.
  • Early treatment choices may significantly influence later-stage disease management and patient survival.

Conclusions:

  • Targeted therapies targeting the EGFR/HER1 pathway are crucial for NSCLC management.
  • Further research is needed to establish best practices for integrating these agents into treatment protocols.
  • Understanding the long-term impact of early treatment decisions is essential for improving NSCLC patient outcomes.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.